Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279915 | 0.84 | KDR (0.46) | KDRFGFR1 | |
| SCHEMBL4283735 | 0.83 | KDR (0.49) | KDRFGFR1 | |
| SCHEMBL4278293 | 0.83 | KDR (0.55) | KDRFGFR1 | |
| SCHEMBL4287812 | 0.81 | KDR (0.45) | KDRFGFR1 | |
| SCHEMBL4771707 | 0.81 | KDR (0.42) | KDRFGFR1EGFR | |
| SCHEMBL4286017 | 0.80 | KDR (0.51) | KDRFGFR1EGFRERBB2ERBB3 | |
| SCHEMBL4285980 | 0.79 | KDR (0.50) | KDRFGFR1EGFRERBB2ERBB3 | |
| SCHEMBL4284980 | 0.79 | KDR (0.56) | KDRFGFR1 | |
| SCHEMBL2748778 | 0.76 | FGFR1 (0.44) | KDRFGFR1EGFRERBB2ERBB3 | |
| SCHEMBL4283173 | 0.73 | KDR (0.39) | KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1904498-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007004749-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | KDR 2/4885FGFR1 14/4885EGFR 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.